**Pliant Therapeutics, Inc. Reports Fiscal Year 2025 Results, Prioritizes Oncology Program**

Pliant Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on integrin-based therapeutics, reported a net loss of $149.3 million for the year ended December 31, 2025, compared to a net loss of $210.3 million for the previous year. The company generated no revenue for either fiscal year. Research and development expenses totaled $109.2 million in 2025, a decrease from $169.3 million in 2024, primarily due to the discontinuation of the BEACON-IPF Phase 2b trial and subsequent cessation of bexotegrast development for idiopathic pulmonary fibrosis (IPF). General and administrative expenses also decreased to $47.2 million from $59.1 million, mainly due to personnel-related expenses following restructuring activities.

The company's cash, cash equivalents, restricted cash, and short-term investments amounted to $192.4 million as of December 31, 2025. Net cash used in operating activities was $128.3 million, while net cash provided by investing activities was $134.3 million. The company completed a voluntary prepayment of its Amended Loan Agreement with Oxford Finance LLC in October 2025, resulting in a loss on extinguishment of debt of $1.8 million. Based on its current operating plan, Pliant believes its existing capital resources will be sufficient to fund anticipated operating expenses and capital expenditure requirements for the next 12 months and beyond.

Pliant's strategic focus has shifted towards its oncology program, PLN-101095, an oral, small molecule dual selective inhibitor of αvβ8 and αvβ1 integrins. Positive data from a Phase 1 trial of PLN-101095 in combination with pembrolizumab in solid tumors resistant to immune checkpoint inhibitors was announced in 2025. The company plans to accelerate the development of PLN-101095 with the initiation of a Phase 1b indication expansion trial assessing non-small cell lung cancer (NSCLC) and other tumor types in 2026. Minnie Kuo was appointed Chief Operating Officer, expanding her role to oversee clinical operations, early development, program management, regulatory affairs, and compliance.

As of December 31, 2025, Pliant had 49 full-time employees, with 30 engaged in research and development activities and 19 in general and administrative roles. The company is subject to various risks, including those related to its financial position, research and development, intellectual property, reliance on third parties, and regulatory compliance. Pliant's common stock is listed on the Nasdaq Global Select Market under the symbol "PLRX," with 61,449,290 shares issued and outstanding as of March 5, 2026. The aggregate market value of the voting and non-voting common equity held by non-affiliates of the Registrant, based on the closing price of the shares of common stock on The NASDAQ Stock Market on June 30, 2025, was $69,542,244.

About PLIANT THERAPEUTICS, INC.

Pliant Therapeutics is a biopharmaceutical company focused on discovering and developing therapies for fibrotic diseases. Its core pipeline includes oral small molecules targeting integrins to treat idiopathic pulmonary fibrosis, primary sclerosing cholangitis, and resistant solid tumors. The company leverages proprietary biology, medicinal chemistry, and biomarker tools to de-risk and accelerate fibrosis drug development for orphan and high unmet need indications.

This description was generated via AI from an annual report. Updated 8 months ago.

About 10-K Filings

A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.

Key points about the 10-K:

  • Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
  • Content: It includes:
    • Detailed financial statements audited by an independent accounting firm
    • Management's Discussion and Analysis (MD&A) of financial condition and results
    • Description of the company's business, properties, and legal proceedings
    • Risk factors and market risks
    • Executive compensation and corporate governance information
  • Importance: Considered the most comprehensive and important document a public company files with the SEC.
  • Length: Often exceeds 100 pages due to its extensive and detailed nature.

Our Methodology

AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.

Our method:

  1. Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
  2. AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
  3. Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
  4. Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
  5. Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Read more about AssetRoom

Feedback & Corrections

Spot an error or have a suggestion? Contact us.